$EMCG
Embrace Change Acquisition Corp Stock $emcg

$emcg Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000182912624005033 Filed on July 26, 2024

Income Statement

Concept	2024 Q3	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$325.1K	$1.062M
YoY Change		62.72%	200.03%
Operating Profit	-$350.8K		-$1.062M
YoY Change	-28.11%		200.02%
Interest Expense	$3.513K	$780.2K	$3.487M
YoY Change	-99.63%	21.7%	355.95%
% of Operating Profit
Other Income/Expense, Net	$578.5K
YoY Change	-38.65%
Pretax Income		$455.1K	$2.424M
YoY Change		3.13%	490.38%
Income Tax
% Of Pretax Income
Net Earnings	$227.6K	$455.1K	$2.424M
YoY Change	-49.95%	3.13%	490.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share		$0.06	$0.27
COMMON SHARES
Basic Shares Outstanding	5.127M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$5.310K	$5.310K
YoY Change		-98.68%	-98.68%
Cash & Equivalents	$13.05K	$5.308K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$20.25K
Receivables
Other Receivables
Total Short-Term Assets	$33.30K	$5.308K	$5.310K
YoY Change	24.68%	-98.68%	-98.68%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$56.23M	$56.23M
YoY Change		-26.54%	-26.54%
Other Assets
YoY Change
Total Long-Term Assets	$25.78M	$56.23M	$56.23M
YoY Change	-59.75%	-26.54%	-26.54%
TOTAL ASSETS
Total Short-Term Assets	$33.30K	$5.308K	$5.310K
Total Long-Term Assets	$25.78M	$56.23M	$56.23M
Total Assets	$25.82M	$56.24M	$56.24M
YoY Change	-59.72%	-26.91%	-26.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses		$1.077M	$1.077M
YoY Change		585.93%	585.93%
Deferred Revenue
YoY Change
Short-Term Debt		$400.1K	$400.1K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.817M	$1.532M	$1.532M
YoY Change	203.49%	875.42%	875.43%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$2.588M	$2.588M
YoY Change		0.0%	0.0%
Total Long-Term Liabilities		$2.588M	$2.588M
YoY Change		0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.817M	$1.532M	$1.532M
Total Long-Term Liabilities		$2.588M	$2.588M
Total Liabilities	$5.783M	$4.119M	$4.119M
YoY Change	64.49%	50.09%	50.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.750M	-$4.114M
YoY Change	64.79%	75.73%
Common Stock	$230.00	$230.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.750M	-$4.114M	$52.12M
YoY Change
Total Liabilities & Shareholders Equity	$25.82M	$56.24M	$56.24M
YoY Change	-59.72%	-26.91%	-26.91%

Cashflow Statement

Concept	2024 Q3	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$227.6K	$455.1K	$2.424M
YoY Change	-49.95%	3.13%	490.38%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$148.6K	-$352.4K
YoY Change		94.44%	78.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$8.611M	$23.80M
YoY Change			-131.4%
Cash From Investing Activities		$8.611M	$23.80M
YoY Change			-131.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$24.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-8.466M	-$23.84M
YoY Change			-131.22%
NET CHANGE
Cash From Operating Activities		-148.6K	-$352.4K
Cash From Investing Activities		8.611M	$23.80M
Cash From Financing Activities		-8.466M	-$23.84M
Net Change In Cash		-3.900K	-$397.7K
YoY Change		-94.9%	-199.82%
FREE CASH FLOW
Cash From Operating Activities		-$148.6K	-$352.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001869601
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2022Q4	CIK0001869601	Due To Related Party DueToRelatedParty		usd
CY2022Q4	CIK0001869601	Convertible Promissory Note Related Party ConvertiblePromissoryNoteRelatedParty		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022	CIK0001869601	Issuance Of Representative Shares IssuanceOfRepresentativeShares		usd
CY2022	CIK0001869601	Accretion Additional Paidin Capital To Deficit AccretionAdditionalPaidinCapitalToDeficit		usd
CY2022	CIK0001869601	Investment Of Cash In Trust Account InvestmentOfCashInTrustAccount		usd
CY2023	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments		usd
CY2022	CIK0001869601	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption		usd
CY2023	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	CIK0001869601	Proceeds From Convertible Promissory Note Related Party ProceedsFromConvertiblePromissoryNoteRelatedParty		usd
CY2022	CIK0001869601	Proceeds From Related Party For Working Capital Purpose ProceedsFromRelatedPartyForWorkingCapitalPurpose		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	CIK0001869601	Deferred Offering Costs Included In Promissory Note DeferredOfferingCostsIncludedInPromissoryNote		usd
CY2023	CIK0001869601	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
CY2023	CIK0001869601	Initial Valuation Of Ordinary Shares Subject To Possible Redemption InitialValuationOfOrdinarySharesSubjectToPossibleRedemption		usd
CY2023	CIK0001869601	Accretion Of Apic To Deficit AccretionOfApicToDeficit		usd
CY2022	CIK0001869601	Accretion Of Offering Cost To Deficit AccretionOfOfferingCostToDeficit		usd
CY2022	CIK0001869601	Extension Funds Attributable To Ordinary Shares To Redemption ExtensionFundsAttributableToOrdinarySharesToRedemption		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity File Number EntityFileNumber	001-41397
CY2023	dei	Entity Registrant Name EntityRegistrantName	EMBRACE CHANGE ACQUISITION CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5186 Carroll Canyon Rd
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	78998575	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5127282	shares
CY2023	dei	Auditor Firm AuditorFirmId	206
CY2023	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023	dei	Auditor Firm AuditorFirmId	206
CY2023Q4	us-gaap	Cash Cash	5308	usd
CY2022Q4	us-gaap	Cash Cash	403012	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	521	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5308	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	403533	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	56231052	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	76541453	usd
CY2023Q4	us-gaap	Assets Assets	56236360	usd
CY2022Q4	us-gaap	Assets Assets	76944986	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1077258	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	157051	usd
CY2023Q4	CIK0001869601	Due To Related Party DueToRelatedParty	54535	usd
CY2023Q4	CIK0001869601	Convertible Promissory Note Related Party ConvertiblePromissoryNoteRelatedParty	400112	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1531905	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	157051	usd
CY2023Q4	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2587499	usd
CY2022Q4	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2587499	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4119404	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2744550	usd
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5127282	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	7392855	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7392855	shares
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.35
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56231052	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	76541453	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2295893	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2295893	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2295893	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2295893	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7392855	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	230	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	230	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4114326	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2341247	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4114096	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2341017	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56236360	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	76944986	usd
CY2023	CIK0001869601	Formation And Operating Costs FormationAndOperatingCosts	1062206	usd
CY2022	CIK0001869601	Formation And Operating Costs FormationAndOperatingCosts	354043	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1062206	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-354043	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2424391	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	410646	usd
CY2023	CIK0001869601	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	9014565	shares
CY2022	CIK0001869601	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	4898504	shares
CY2023	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.27
CY2022	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.08
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2341017	usd
CY2023	CIK0001869601	Accretion Of Offering Costs To Deficit AccretionOfOfferingCostsToDeficit	210873	usd
CY2023	CIK0001869601	Adjustment To General Reserves Amount Deposited Into Trust Account Subject To Redemption AdjustmentToGeneralReservesAmountDepositedIntoTrustAccountSubjectToRedemption	-500000	usd
CY2023	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	-3486597	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2424391	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4114096	usd
CY2022	CIK0001869601	Sale Of Ipo Unit SaleOfIpoUnit	73928550	usd
CY2022	CIK0001869601	Sale Of Private Placement Units SaleOfPrivatePlacementUnits	3737500	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3898030	usd
CY2022	us-gaap	Stockholders Equity Other StockholdersEquityOther	-75776764	usd
CY2022	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	-764689	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	410646	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2341017	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2424391	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	410646	usd
CY2023	CIK0001869601	Investment Income Earned On Investments Held In Trust Account InvestmentIncomeEarnedOnInvestmentsHeldInTrustAccount	3486597	usd
CY2022	CIK0001869601	Investment Income Earned On Investments Held In Trust Account InvestmentIncomeEarnedOnInvestmentsHeldInTrustAccount	764689	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-521	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	521	usd
CY2023	CIK0001869601	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	709334	usd
CY2022	CIK0001869601	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	157051	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-352351	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-197513	usd
CY2023	CIK0001869601	Investment Of Cash In Trust Account InvestmentOfCashInTrustAccount	500000	usd
CY2022	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	75776764	usd
CY2023	CIK0001869601	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption	24296998	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23796998	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75776764	usd
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	73214265	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3737500	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	24296998	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	419600	usd
CY2023	CIK0001869601	Proceeds From Convertible Promissory Note Related Party ProceedsFromConvertiblePromissoryNoteRelatedParty	400112	usd
CY2023	CIK0001869601	Proceeds From Related Party For Working Capital Purpose ProceedsFromRelatedPartyForWorkingCapitalPurpose	54535	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	159478	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-23842351	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76372687	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-397704	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	398410	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	403012	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4602	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5308	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	403012	usd
CY2022	CIK0001869601	Deferred Offering Costs Included In Promissory Note DeferredOfferingCostsIncludedInPromissoryNote	-12198	usd
CY2022	CIK0001869601	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	2587499	usd
CY2022	CIK0001869601	Initial Valuation Of Ordinary Shares Subject To Possible Redemption InitialValuationOfOrdinarySharesSubjectToPossibleRedemption	75776764	usd
CY2023	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption1 RemeasurementOfOrdinarySharesSubjectToRedemption1	3486597	usd
CY2022	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption1 RemeasurementOfOrdinarySharesSubjectToRedemption1	764689	usd
CY2022	CIK0001869601	Accretion Of Apic To Deficit AccretionOfApicToDeficit	1983974	usd
CY2023	CIK0001869601	Accretion Of Offering Cost To Deficit AccretionOfOfferingCostToDeficit	210873	usd
CY2023	CIK0001869601	Extension Funds Attributable To Ordinary Shares To Redemption ExtensionFundsAttributableToOrdinarySharesToRedemption	500000	usd
CY2022Q3	CIK0001869601	Incurred Offering Costs IncurredOfferingCosts	3898030	usd
CY2022Q3	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2587499	usd
CY2022Q3	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	75776764	usd
CY2022Q3	CIK0001869601	Restricted Investment Price Per Share RestrictedInvestmentPricePerShare	10.25	shares
CY2023Q4	CIK0001869601	Net Tangible Assets Required For Consummation Of Business Combination NetTangibleAssetsRequiredForConsummationOfBusinessCombination	5000001	usd
CY2023Q4	us-gaap	Share Price SharePrice	10.25
CY2023Q3	CIK0001869601	Description Of Business Combination Period DescriptionOfBusinessCombinationPeriod	must consummate a business combination (the “Combination Period”) twelve (12) times for an additional one (1) month each time, from August 12, 2023 (i.e. the end of 12 months from the consummation of its Initial Public Offering, the “Termination Date”) to August 12, 2024 (the “Extended Date”)
CY2023Q3	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	100000	usd
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1550710	shares
CY2023	CIK0001869601	Description Of Business Organization DescriptionOfBusinessOrganization	From August 2023 to December 2023, the Company deposited five tranches of $100,000, for an aggregated of $500,000 into the Trust Account, extending the Termination Date to January 12, 2024. From January 2024 to March 2024, the Company deposited additional three tranches of $100,000, for an aggregated of $300,000 into the Trust Account, extending the Termination Date to April 12, 2024. Up to the date the financial statements were issued, the Company has not deposited the required extension contributions of $400,000 into the Trust Account, to extend the Termination Date to August 12, 2024.
CY2023	CIK0001869601	Dissolution Expense DissolutionExpense	50000	usd
CY2023Q4	us-gaap	Cash Cash	5308	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	159478	usd
CY2023Q3	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	100000	usd
CY2023Q3	CIK0001869601	Extension Contributions ExtensionContributions	400000	usd
CY2023Q4	us-gaap	Cash Cash	5308	usd
CY2022Q4	us-gaap	Cash Cash	403012	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	56231052	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	76541453	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zEoyYw1miTY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_zH2TY4dnHfh">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023	CIK0001869601	Incurred Offering Costs IncurredOfferingCosts	3898030	usd
CY2023Q4	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2587499	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	571245	usd
CY2023	CIK0001869601	Accretion Of Offering Costs To Deficit AccretionOfOfferingCostsToDeficit	210873	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7392855	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7392855	shares
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zjcXgjvGZDH" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zniXEz1ktc06">Concentration of Credit Risk</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zcxekLPLL1Lf" title="Cash, FDIC insured amount">250,000</span>. On December 31, 2023, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. On December 31, 2023 and 2022, the Company had $<span id="xdx_904_eus-gaap--Cash_iI_pp0p0_c20231231_zjzG8txEhvMe" title="Cash">5,308</span> and $<span id="xdx_90C_eus-gaap--Cash_iI_pp0p0_c20221231_z3SFC1hbF1bk" title="Cash">403,012</span> cash, respectively, held in operating bank account.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Cash Cash	5308	usd
CY2022Q4	us-gaap	Cash Cash	403012	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2424391	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	410646	usd
CY2023	CIK0001869601	Denominator Weighted Average Number Of Ordinary Shares DenominatorWeightedAverageNumberOfOrdinaryShares	9014565	shares
CY2022	CIK0001869601	Denominator Weighted Average Number Of Ordinary Shares DenominatorWeightedAverageNumberOfOrdinaryShares	4898504	shares
CY2023	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.27
CY2022	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.08
CY2022Q3	CIK0001869601	Incurred Offering Costs IncurredOfferingCosts	3898030	usd
CY2022Q3	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2587499	usd
CY2023	CIK0001869601	Accretion Of Offering Costs To Deficit AccretionOfOfferingCostsToDeficit	210873	usd
CY2023Q4	CIK0001869601	Due To Related Party DueToRelatedParty	54535	usd
CY2022Q3	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	159478	usd
CY2023Q4	CIK0001869601	Convertible Promissory Notes ConvertiblePromissoryNotes	100000	usd
CY2023Q4	CIK0001869601	Convertible Promissory Notes ConvertiblePromissoryNotes	190112	usd
CY2023Q4	CIK0001869601	Convertible Promissory Notes ConvertiblePromissoryNotes	100000	usd
CY2023Q4	CIK0001869601	Promissory Note Related Party PromissoryNoteRelatedParty	400112	usd
CY2023	CIK0001869601	Underwriting Discount Percentage UnderwritingDiscountPercentage	0.0100	pure
CY2023	CIK0001869601	Deferred Underwriting Commission Percentage DeferredUnderwritingCommissionPercentage	0.0350	pure
CY2023	CIK0001869601	Unrestricted Shares UnrestrictedShares	200000	shares
CY2023	CIK0001869601	Percenatge Of Gross Proceeds Of The Ordinary Shares PercenatgeOfGrossProceedsOfTheOrdinaryShares	0.0100	pure
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5127282	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	7392855	shares
CY2023	CIK0001869601	Unrestricted Shares UnrestrictedShares	200000	shares

Files In Submission

Name	View Source	Status
0001829126-24-005033-index-headers.html	Edgar Link	pending
0001829126-24-005033-index.html	Edgar Link	pending
0001829126-24-005033.txt	Edgar Link	pending
0001829126-24-005033-xbrl.zip	Edgar Link	pending
cik0001869601-20231231.xsd	Edgar Link	pending
embracechange_10k.htm	Edgar Link	pending
embracechange_ex31-1.htm	Edgar Link	pending
embracechange_ex31-2.htm	Edgar Link	pending
embracechange_ex32.htm	Edgar Link	pending
embracechange_ex4-7.htm	Edgar Link	pending
embracechange_ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cik0001869601-20231231_cal.xml	Edgar Link	unprocessable
cik0001869601-20231231_def.xml	Edgar Link	unprocessable
cik0001869601-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
embracechange_10k_htm.xml	Edgar Link	completed
cik0001869601-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMCG
Embrace Change Acquisition Corp Stock $emcg

2024 Q3 Form 10-K Financial Statement

#000182912624005033 Filed on July 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMCG Embrace Change Acquisition Corp Stock $emcg

2024 Q3 Form 10-K Financial Statement

#000182912624005033 Filed on July 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMCG
Embrace Change Acquisition Corp Stock $emcg